Growing evidence supports 4CMenB effectiveness

Affiliations

¹ Immunisation Department, Public Health England, London NW1 5EQ, UK. Electronic address: shamez.ladhani@phe.gov.uk.
² Meningococcal Reference Unit, Public Health England, London NW1 5EQ, UK.
³ Statistics, Modelling and Economics Department, Public Health England, London NW1 5EQ, UK.

Comment

Shamez N Ladhani et al. Lancet Infect Dis. 2018 Apr.

. 2018 Apr;18(4):370-371.

doi: 10.1016/S1473-3099(18)30051-3. Epub 2018 Jan 19.

¹ Immunisation Department, Public Health England, London NW1 5EQ, UK. Electronic address: shamez.ladhani@phe.gov.uk.
² Meningococcal Reference Unit, Public Health England, London NW1 5EQ, UK.
³ Statistics, Modelling and Economics Department, Public Health England, London NW1 5EQ, UK.

No abstract available

Comment on

Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, Cultrera R, Villari P, Ricciardi W, Ioannidis JPA, Contopoulos-Ioannidis DG. Flacco ME, et al. Lancet Infect Dis. 2018 Apr;18(4):461-472. doi: 10.1016/S1473-3099(18)30048-3. Epub 2018 Jan 19. Lancet Infect Dis. 2018. PMID: 29371070